A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study
T Masuishi1, H Taniguchi1, D Kotani2
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Background:
Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC).
Patients And Methods:
Patients with BRAF V600E mutant mCRC who received at least one prior regimen were administered intravenous eribulin. The primary endpoint was the objective response rate (ORR). Biomarker analyses were carried out using tumor and serial blood samples. Patients with reduced tumor size and/or progression-free survival (PFS) of >6 months were classified into the good response group, and the remaining patients were classified into the poor response group.
Results:
Among the 27 patients enrolled, the ORR was 0% (95% confidence interval 0.0% to 12.8%), the disease control rate was 41%, the median PFS was 1.4 months, and the median survival time was 5.3 months (median follow-up, 5.3 months). Of 26 patients for whom tumors for RNA sequencing were available, all four patients in the good response group had the BRAF mutant (BM)2 subtype on gene expression analysis of BM subtype, whereas 22 patients in the poor response group had the BM1 (n = 8) or BM2 (n = 14) subtypes (P = 0.07). The proportion of patients with decreasing BRAF V600E relative clonality at the start of the second cycle was 75% and 11% in the good response and poor response groups, respectively (P = 0.02). Grade 3 and 4 adverse events included neutropenia (63%) and febrile neutropenia (22%).
Conclusions:
This phase II study of eribulin for patients with BRAF V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis.
Insights
Eribulin did not show efficacy in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC), failing to meet the primary endpoint. The BRAF mutant 2 (BM2) subtype may indicate potential efficacy, warranting further investigation.
Area of Science:
- Oncology
- Clinical Pharmacology
- Genomics
Background:
- Microtubule inhibitors show promise against BRAF V600E mutant colorectal cancer.
- A phase II study evaluated eribulin's efficacy and safety in this patient population.
Purpose of the Study:
- To assess the efficacy and safety of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC).
- To explore potential predictive biomarkers for eribulin response.
Main Methods:
- A multicenter phase II study administered intravenous eribulin to patients with previously treated BRAF V600E mutant mCRC.
- Objective response rate (ORR) was the primary endpoint; biomarker analyses included gene expression and BRAF V600E relative clonality.
- Patients were categorized into good or poor response groups based on tumor size and progression-free survival (PFS).
Main Results:
- The study enrolled 27 patients; the ORR was 0%, with a median PFS of 1.4 months and median survival of 5.3 months.
- The BRAF mutant 2 (BM2) subtype was more frequent in the good response group (4/4 patients) compared to the poor response group (14/22 patients).
- Decreasing BRAF V600E relative clonality early in treatment was associated with a good response (75% vs 11%). Common adverse events included neutropenia (63%) and febrile neutropenia (22%).
Conclusions:
- Eribulin did not meet the primary endpoint for efficacy in BRAF V600E mutant mCRC.
- The BM2 subtype may serve as a predictive biomarker for eribulin efficacy, but requires further validation.
- The study highlights the need for targeted therapies and biomarker-driven approaches in mCRC treatment.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers